{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:20:39Z","timestamp":1794583239761,"version":"4.9.1"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Myelofibrosis is a progressive disease characterized by accumulation of extracellular matrix in the bone marrow (BM), which impairs normal hematopoiesis. While Janus kinase inhibitors reduce spleen volume and provide symptomatic improvement, they do not resolve BM fibrosis and may cause or exacerbate anemia and thrombocytopenia. An antifibrotic therapy capable of normalizing the BM microenvironment and function remains a significant gap in the current treatment landscape. Myelofibrosis is associated with elevated expression of lysyl oxidases, enzymes responsible for maturation of the most abundant extracellular matrix proteins: collagen and elastin. PXS-5505 is a novel pan-lysyl oxidase inhibitor designed to exert an antifibrotic effect by preventing the cross-linking of collagen and elastin. PXS5505-MF-101 is a multicenter phase I\/IIa study of PXS-5505 in myelofibrosis patients which included a dose escalation phase (DEP) and a cohort expansion phase (CEP). Primary objectives of the study were to determine the safety and tolerability of PXS-5505 and to define dosing for future studies. The DEP demonstrated that the highest dose tested, 200 mg BID, was safe and achieved robust systemic reduction of lysyl oxidase activity; this dose was, therefore, selected for the CEP. Twenty-four patients (median age 72 years) with relapsed or refractory myelofibrosis were recruited into the CEP and 54% (13\/24) completed 24 weeks of treatment. PXS-5505 was well tolerated and reached steady-state concentrations by day 28. Over the 24-week treatment period preliminary indications of clinical efficacy, including a reduction in BM collagen, were evident. Overall, these data support continued investigation of PXS-5505. (ClinicalTrials.gov identifier: NCT04676529).<\/jats:p>","DOI":"10.3324\/haematol.2024.287231","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:08:23Z","timestamp":1744859303000},"page":"2376-2387","source":"Crossref","is-referenced-by-count":14,"title":["A phase I\/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis"],"prefix":"10.3324","volume":"110","author":[{"given":"Pankit","family":"Vachhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuh Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Baskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Jarolimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Leadbetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"80237","doi-asserted-by":"crossref","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023; 98(5):801-821.","DOI":"10.1002\/ajh.26857"},{"key":"80238","doi-asserted-by":"crossref","unstructured":"Mascarenhas JO, Verstovsek S. The clinical dilemma of JAK inhibitor failure in myelofibrosis: predictive characteristics and outcomes. Cancer. 2022; 128(14):2717-2727.","DOI":"10.1002\/cncr.34222"},{"key":"80239","doi-asserted-by":"crossref","unstructured":"Ghosh K, Shome DK, Kulkarni B, Ghosh MK, Ghosh K. Fibrosis and bone marrow: understanding causation and pathobiology. J Transl Med. 2023; 21(1):703.","DOI":"10.1186\/s12967-023-04393-z"},{"key":"80240","doi-asserted-by":"crossref","unstructured":"Trackman PC. Lysyl oxidase isoforms and potential therapeutic opportunities for fibrosis and cancer. Expert Opin Ther Targets. 2016; 20(8):935-945.","DOI":"10.1517\/14728222.2016.1151003"},{"key":"80241","doi-asserted-by":"crossref","unstructured":"Tadmor T, Bejar J, Attias D. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol. 2013; 88(5):355-358.","DOI":"10.1002\/ajh.23409"},{"key":"80242","doi-asserted-by":"crossref","unstructured":"Piasecki A, Leiva O, Ravid K. Lysyl oxidase inhibition in primary myelofibrosis: a renewed strategy. Arch Stem Cell Ther. 2020; 1(1):23-27.","DOI":"10.46439\/stemcell.1.005"},{"key":"80243","doi-asserted-by":"crossref","unstructured":"Leiva O, Ng SK, Matsuura S. Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice. Int J Hematol. 2019; 110(6):699-708.","DOI":"10.1007\/s12185-019-02751-6"},{"key":"80244","doi-asserted-by":"crossref","unstructured":"Chitty JL, Yam M, Perryman L. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nat Cancer. 2023; 4(9):1326-1344.","DOI":"10.1038\/s43018-023-00614-y"},{"key":"80245","doi-asserted-by":"crossref","unstructured":"Eliades A, Papadantonakis N, Bhupatiraju A. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem. 2011; 286(31):27630-27638.","DOI":"10.1074\/jbc.M111.243113"},{"key":"80246","doi-asserted-by":"crossref","unstructured":"Yao Y, Findlay A, Stolp J, Rayner B, Ask K, Jarolimek W. Pan-lysyl oxidase inhibitor PXS-5505 ameliorates multiple-organ fibrosis by inhibiting collagen crosslinks in rodent models of systemic sclerosis. Int J Mol Sci. 2022; 23(10):5533.","DOI":"10.3390\/ijms23105533"},{"key":"80247","doi-asserted-by":"crossref","unstructured":"Burchard PR, Ruffolo LI, Ullman NA. Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy. Hepatol Commun. 2024; 8(8):e05202.","DOI":"10.1097\/HC9.0000000000000502"},{"key":"80248","unstructured":"Australian New Zealand Clinical Trial Registry. A single ascending dose and multiple ascending dose phase 1 study to evaluate safety tolerability, pharmacokinetics (PK), and pharmacodynamics of PXS-5505A administered orally in healthy adult males. 2025. Publisher Full Text|"},{"key":"80249","doi-asserted-by":"crossref","unstructured":"How J, Liu Y, Lombardi Story J. Evaluation of a pan-lysyl oxidase inhibitor, PXS-5505, in myelofibrosis: a phase I, randomized, placebo controlled double blind study in healthy adults. Blood. 2020; 136(Supplement 1):16.","DOI":"10.1182\/blood-2020-139223"},{"key":"80250","doi-asserted-by":"crossref","unstructured":"Barbui T, Thiele J, Gisslinger H. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2):15.","DOI":"10.1038\/s41408-018-0054-y"},{"key":"80251","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"80252","doi-asserted-by":"crossref","unstructured":"Cardellino A, Zhang S, Phiri K, Gelhorn H, Cutts K. Patient (pt) interview-based content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0). J Clin Oncol. 2024; 42:e23106.","DOI":"10.1200\/JCO.2024.42.16_suppl.e23106"},{"key":"80253","doi-asserted-by":"crossref","unstructured":"Findlay A, Turner C, Schilter H. An activity\u2010based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti\u2010fibrotic therapeutic strategies. Clin Transl Med. 2021; 11(11):e572.","DOI":"10.1002\/ctm2.572"},{"key":"80254","doi-asserted-by":"crossref","unstructured":"Yang N, Cao DF, Yin XX, Zhou HH, Mao XY. Lysyl oxidases: emerging biomarkers and therapeutic targets for various diseases. Biomed Pharmacother. 2020; 131:110791.","DOI":"10.1016\/j.biopha.2020.110791"},{"key":"80255","doi-asserted-by":"crossref","unstructured":"Keiser HR, Sjoerdsma A. Studies on beta-aminopropionitrile in patients with scleroderma. Clin Pharmacol Ther. 1967; 8(4):593-602.","DOI":"10.1002\/cpt196784593"},{"key":"80256","doi-asserted-by":"crossref","unstructured":"Kvasnicka HM, Beham-Schmid C, Bob R. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. Histopathology. 2016; 68(6):905-915.","DOI":"10.1111\/his.12871"},{"key":"80257","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023; 16(1):82.","DOI":"10.1186\/s13045-023-01471-z"},{"key":"80258","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Talpaz M, Wadleigh M. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial. Haematologica. 2024; 109(6):1977-1983.","DOI":"10.3324\/haematol.2023.284410"},{"key":"80259","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Foltz L, Gupta V. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023; 108(10):2730-2742.","DOI":"10.3324\/haematol.2022.282411"},{"key":"80260","doi-asserted-by":"crossref","unstructured":"Ryou H, Sirinukunwattana K, Wood R. Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: an insight from a phase II clinical study of zinpentraxin alfa. Hemasphere. 2024; 8(6):e105.","DOI":"10.1002\/hem3.105"},{"key":"80261","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Savona MR, Mesa RA. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Br J Haematol. 2017; 176(6):939-949.","DOI":"10.1111\/bjh.14501"},{"key":"80262","doi-asserted-by":"crossref","unstructured":"Bell JA, Davies ER, Brereton CJ. Spatial transcriptomic validation of a biomimetic model of fibrosis enables reevaluation of a therapeutic antibody targeting LOXL2. Cell Rep Med. 2024; 5(9):101695.","DOI":"10.1016\/j.xcrm.2024.101695"},{"key":"80263","doi-asserted-by":"crossref","unstructured":"Leiva O, Ng SK, Chitalia S, Balduini A, Matsuura S, Ravid K. The role of the extracellular matrix in primary myelofibrosis. Blood Cancer J. 2017; 7(2):e525.","DOI":"10.1038\/bcj.2017.6"},{"key":"80264","doi-asserted-by":"crossref","unstructured":"Harrison C, Mascarenhas J, Cilloni D. P1024: MYLOX-1: a phase II study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOLX2 inhibitor GB2064 (with focus on bone marrow collagen) in patients with myelofibrosis. Hemasphere. 2023; 7:e87048.","DOI":"10.1097\/01.HS9.0000970996.87048.d4"},{"key":"80265","doi-asserted-by":"crossref","unstructured":"Lucero HA, Ravid K, Grimsby JL. Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem. 2008; 283(35):24103-24117.","DOI":"10.1074\/jbc.M709897200"},{"key":"80266","doi-asserted-by":"crossref","unstructured":"Palandri F, Breccia M, Bonifacio M. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020; 126(6):1243-1252.","DOI":"10.1002\/cncr.32664"},{"key":"80267","doi-asserted-by":"crossref","unstructured":"Kuykendall AT, Shah S, Talati C. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018; 97(3):435-441.","DOI":"10.1007\/s00277-017-3194-4"},{"key":"80268","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Foltz LM. PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood. 2015; 126(23):56.","DOI":"10.1182\/blood.V126.23.56.56"},{"key":"80269","doi-asserted-by":"crossref","unstructured":"Palandri F, Palumbo GA, Elli EM. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021; 11(1):4.","DOI":"10.1038\/s41408-020-00392-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12032\/78288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12032\/78875","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12032\/78288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:34Z","timestamp":1794046114000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287231","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}